Allero: treating food-related immune diseases through an oral patch

Allero emerged from stealth last year to develop an oral patch-based immunotherapy that could lead to better compliance and fewer safety risks than other treatments in the expanding food allergy and Celiac disease development landscapes.

The company, which was founded in 2016 with undisclosed seed funding, was formed around the idea that an oromucosal patch can promote antigen-specific immune tolerance with minimal systemic exposure. ...